Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Vera, R; Ibarrola-de-Andres, C; Adeva, J; Perez-Rojas, J; Garcia-Alfonso, P; Rodriguez-Gil, Y; Macarulla, T; Serrano-Pinol, T; Mondejar, R; Madrigal-Rubiales, B.

Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

Clinical & Translational Oncology. 2022; 24(11): 2107-2119 Nº de citas: 3 [doi:10.1007/s12094-022-02873-0]

Climent, MA; Font, A; Duran, I; Puente, J; Mendez-Vidal, MJ; Saez, MI; Lobera, CS; Arija, JAA; Gonzalez-Del-Alba, A; Sanchez-Hernandez, A; Fita, MJJ; Esteban, E; Alonso-Gordoa, T; Gonzalez, BM; Maroto, P; Lazaro-Quintela, M; Cassinello-Espinosa, J; Perez-Valderrama, B; Garcias, C; Castellano, D.

A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

EUROPEAN JOURNAL OF CANCER. 2022; 175: 110-119 Nº de citas: 10 [doi:10.1016/j.ejca.2022.08.002]

de la Rosa, CA; Castellanos, PC; Lazaro-Quintela, M; Domine, M; Estevez, SV; Lopez-Vivanco, G; Perez, JLF; Romero, JLA; Delgado, LF; Giron, CG; Tain, PD; Alvarez, RA; Sanchis, PM; Canton, IF; Abos, IM; Aguillo, MM; Gutierrez, LGA; Granados, ALO; Cabellos, RA; Sebastian, AG; Sifuentes, LFG; Reguart, N.

Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

LUNG CANCER. 2022; 173: 83-93 Nº de citas: 10 [doi:10.1016/j.lungcan.2022.09.010]

Quinaglia T; Gongora C; Awadalla M; Hassan MZO; Zafar A; Drobni ZD; Mahmood SS; Zhang L; Coelho-Filho OR; Suero-Abreu GA; Rizvi MA; Sahni G; Mandawat A; Zatarain-Nicolás E; Mahmoudi M; Sullivan R; Ganatra S; Heinzerling LM; Thuny F; Ederhy S; Gilman HK; Sama S; Nikolaidou S; Mansilla AG; Calles A; Cabral M; Fernández-Avilés F; Gavira JJ; González NS; García de Yébenes Castro M; Barac A; Afilalo J; Zlotoff DA; Zubiri L; Reynolds KL; Devereux R; Hung J; Picard MH; Yang EH; Gupta D; Michel C; Lyon AR; Chen CL; Nohria A; Fradley MG; Thavendiranathan P; Neilan TG.

Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis

JACC-Cardiovascular Imaging. 2022; 15(11): 1883-1896 Nº de citas: 26 [doi:10.1016/j.jcmg.2022.06.014]

García Adrián S; Gonzalez, AR; De Castro, EM; Olmos, VP; Moran, LO; del Prado, PM; Fernandez, MS; Burón JDC; Escobar, IG; Galan, JM; Pérez AIF; Neria, F; Lavin, DC; Hernández BLSV; Jimenez-Fonseca, P; Muñoz Martín AJ.

Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis

European Journal of Internal Medicine. 2022; 105: 30-37 Nº de citas: 15 [doi:10.1016/j.ejim.2022.07.020]

Canovas, MS; Garay, DF; Moran, LO; Perez, JR; Rubio, CMG; de Mena, ML; Portero, BO; Castro, JB; Lage, Y; Lavin, DC; Blanco, ABR; de Soignie, AMMF; Perejon, JZB; Colomo, LJ; Boluda, NB; Moreno, JB; Verduguez, TQ; Garrido, CR; Huertas, RM; Puig, CFI; Martin, AJM.

Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group

Clinical & Translational Oncology. 2022; 24(10): 2010-2020 Nº de citas: 22 [doi:10.1007/s12094-022-02860-5]

Carmona-Bayonas, A; Verso, M; Canovas, MS; Perez, JR; de Herreros, MG; del Prado, PM; Perez, IF; Verduguez, TQ; Portero, BO; Olmos, VP; Gomez, D; Ortega, L; Moyano, MS; Brozos, EM; Biosca, M; Rebollo, MA; Sanchez, LT; Perez, CH; Buron, JDC; Lago, NM; Perez, EG; Langa, JM; Segura, PP; de Castro, EM; Jimenez-Fonseca, P; Agnelli, G; Munoz, A.

Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

THROMBOSIS AND HAEMOSTASIS. 2022; 122(10): 1653-1661 Nº de citas: 4 [doi:10.1055/a-1816-8347]

Lope, V; Guerrero-Zotano, A; Ruiz-Moreno, E; Bermejo, B; Antolin, S; Montano, A; Baena-Canada, JM; Vazquez, MR; de Larrea-Baz, NF; Chacon, JI; Garcia-Saenz, JA; Olier, C; Munoz, M; Anton, A; Rovira, PS; Lanza, AA; Gonzalez, S; Oltra, A; Brunet, J; Gregori, JG; Martinez, MT; Calvo, L; Rosell, L; Bezares, S; Pastor-Barriuso, R; Perez-Gomez, B; Martin, M; Pollan, M.

Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGEICAM Study

Cancers. 2022; 14(19): Nº de citas: 9 [doi:10.3390/cancers14194705]

Majem, M; Alvarez, R; Ortega, AL; de Alda, LR; Gordo, R; Garcia, JF; Ivanova-Markova, Y; Gonzalez-Dominguez, A; San Cristobal, RS; Rojo, F.

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain

Global & Regional Health Technology Assessment. 2022; 9: 82-90 Nº de citas: 2 [doi:10.33393/grhta.2022.2449]

Galactionova, K; Loibl, S; Salari, P; Marme, F; Martin, M; Untch, M; Bonnefoi, HR; Kim, SB; Bear, HD; McCarthy, N; Gelmon, KA; Garcia-Saenz, JA; Kelly, CM; Reimer, T; Toi, M; Rugo, HS; Gnant, M; Makris, A; Burchardi, N; Schwenkglenks, M.

Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

Frontiers in Oncology. 2022; 12: Nº de citas: 3 [doi:10.3389/fonc.2022.886831]

Vazquez, JC; Pinero, A; de Castro, FJ; Lluch, A; Martin, M; Barnadas, A; Alba, E; Rodriguez-Lescure, A; Rojo, F; Gimenez, J; Sola, I; Quintana, MJ; Bonfill, X; Urrutia, G; Sanchez-Rovira, P.

The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

Clinical & Translational Oncology. 2022; 24(9): 1744-1754 Nº de citas: 7 [doi:10.1007/s12094-022-02824-9]

Larkin J; Weber J; Del Vecchio M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; De la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Long GV; Lobo M; Askelson M; Ascierto PA; Mandalá M.

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

EUROPEAN JOURNAL OF CANCER. 2022; 173: 285-296 Nº de citas: 32 [doi:10.1016/j.ejca.2022.06.041]

Donat-Vargas, C; Guerrero-Zotano, A; Lope, V; Bermejo, B; Casas, A; Baena-Canada, JM; Antolin, S; Sanchez-Rovira, P; Anton, A; Garcia-Saenz, JA; Ramos, M; Munoz, M; de Juan, A; Sanchez, CJ; Chacon, JI; Gil-Gil, M; Conejero, RA; Llombart, A; Bezares, S; de Larrea-Baz, NF; Perez-Gomez, B; Martin, M; Pollan, M.

Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study

EUROPEAN JOURNAL OF CLINICAL NUTRITION. 2022; 76(9): 1343-1346 Nº de citas: 2 [doi:10.1038/s41430-022-01101-w]

Zhu, Z; Turner, NC; Loi, S; Andre, F; Martin, M; Dieras, V; Gelmon, KA; Harbeck, N; Zhang, C; Cao, JQ; Yan, ZM; Lu, DR; Wei, P; VanArsdale, TL; Rejto, PA; Huang, X; Rugo, HS; Loibl, S; Cristofanilli, M; Finn, RS; Liu, Y.

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

npj Precision Oncology. 2022; 6(1): Nº de citas: 22 [doi:10.1038/s41698-022-00297-1]

Gil-Herrero, L; Pollan, M; Martin, M; Lopez-Tarruella, S; Castellanos, M; Casla-Barrio, S.

The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0

SUPPORTIVE CARE IN CANCER. 2022; 30(8): 6745-6754 Nº de citas: 9 [doi:10.1007/s00520-022-06993-9]

Martin, M; Hegg, R; Kim, SB; Schenker, M; Grecea, D; Garcia-Saenz, JA; Papazisis, K; Ouyang, QC; Lacko, A; Oksuzoglu, B; Reeves, J; Okera, M; Testa, L; Shimizu, C; Denduluri, N; Adamchuk, H; Dakhil, S; Wei, R; Forrester, T; Fernandez, MM; Zimmermann, A; Headley, D; Johnston, SRD.

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy A Prespecified Analysis of the monarchE Randomized Clinical Trial

JAMA Oncology. 2022; 8(8): 1190-1194 Nº de citas: 48 [doi:10.1001/jamaoncol.2022.1488]

Hamilton, E; Cortes, J; Ozyilkan, O; Chen, SC; Petrakova, K; Manikhas, A; Jerusalem, G; Hegg, R; Huober, J; Zhang, W; Chen, YY; Martin, M.

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR +, HER2-metastatic breast cancer

BREAST CANCER RESEARCH AND TREATMENT. 2022; 195(1): 55-64 Nº de citas: 18 [doi:10.1007/s10549-022-06662-9]

Siles, MG; Lopez-Beltran, A; Pelechano, P; Vicente, AMG; Sarrio, RG; Pena, EGH; Antolin, AR; Zapatero, A; Arranz, JA; Climent, MA.

Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting

Cancers. 2022; 14(16): Nº de citas: 2 [doi:10.3390/cancers14163968]